Charu Aggarwal, MD, MPH

faculty photo
Leslye M. Heisler Professor for Lung Cancer Excellence
Associate Director, Penn Center for Cancer Care Innovation (PC3I)
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
10-137, South Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-6318
Fax: 215-349-5326
Education:
MD
Lady Hardinge Medical College, New Delhi, India, 2003.
MPH (Health Care Organization and Policy)
University of Alabama at Birmingham, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Aggarwal is the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Perelman School of Medicine.
Dr. Aggarwal specializes in the management of patients with lung cancer, with a specific and clinical research focus on the development of personalized therapeutic approaches, and the discovery and application of biomarkers to guide treatment. She is a world-renowned expert in the application of plasma-based gene sequencing in the management of patients with metastatic lung cancer, and is actively working on implementation of comprehensive testing, and discovery of approaches focusing on early detection, detection of resistance mutations and disease monitoring.

Dr. Aggarwal serves as the Associate Director of Penn Center for Precision Medicine, and Director of Precision Medicine Innovation at the Penn Center for Cancer Care Innovation (PC3I). In her roles, she is actively involved in developing, implementing, and advancing strategic and operational precision medicine initiatives with a focus on those that involve bringing new technologies or approaches to clinical care and ultimately deliver on the promise of personalized cancer therapy.

She is an active member of the Abramson Cancer Center where she serves as Physician Leader for the clinical research program for Airways Malignancies. Dr. Aggarwal performs patient-centered, scientifically relevant novel immunotherapy clinical trials that will make a tangible impact and advance our understanding of immunotherapy in patients with Lung Cancer.

Selected Publications

Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C: PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer Future Oncol Page: doi: 10.1080/14796694.2024.2354160, Jul 2024.

Marmarelis ME, Scholes DG, McWilliams TL, Hwang WT, Kosteva J, Costello MR, Sun L, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy MA, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C: Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial. JCO Oncol Pract(doi: 10.1200/OP.24.00070), Jul 2024.

Wainwright JV, Aggarwal C, Beucker S, Dougherty DW, Gabriel PE, Jacobs LA, Kalman J, Linn KA, Martella AO, Mehta SJ, Rhodes CM, Roy M, Schapira MM, Shulman LN, Steltz J, Stephens Shields AJ, Tan ASL, Thompson JC, Toneff H, Wender RC, Zeb S, Rendle KA, Vachani A, Bekelman JE; Penn TRACE: University of Pennsylvania Telehealth Research Center of Excellence. J Natl Cancer Inst Monogr Jun 2024.

Friedes C, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun LL, Aggarwal C, Marmarelis ME, Doucette A, Cohen RB, Xiao Y, Langer CJ, Bradley J, Feigenberg SJ, Yegya-Raman N.: Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys 118: 1435-1444, Apr 2024.

Sun L, Handorf EA, Zhou Y, Borghaei H, Aggarwal C, Bauman J.: Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels. Lung Cancer Apr 2024.

Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, Li B, Aggarwal C, Cohen RB, Su W, Doucette A, Levin WP, Cengel KA, DiBardino D, Teo BK, O'Reilly SE, Sun L, Bradley JD, Xiao Y, Langer CJ, Feigenberg SJ.: Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys 118: 1445-1454, Apr 2024.

Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Cohen RB, Bauml JM, Langer CJ.: Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC. JTO Clin Res Rep 20(6): 100667, Mar 2024.

Marmarelis ME, Scholes DG, McGrath CM, Priore SF, Roth JJ, Feldman M, Morrissette JJD, Litzky L, Deshpande C, Thompson JC, Doucette A, Gabriel PE, Sun L, Singh AP, Cohen RB, Langer CJ, Carpenter EL, Aggarwal C.: Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. Clin Lung Cancer Mar 2024.

Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ.: Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression. Clin Lung Cancer Jan 2024.

Iocolano M, Yegya-Raman N, Friedes C, Wang X, Kegelman T, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Konski A, Langer CJ, Cohen RB, Sun L, Aggarwal C, Doucette A, Xiao Y, Kevin Teo BK, O'Reilly S, Zou W, Bradley JD, Simone CB 2nd, Feigenberg SJ.: Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era. Cancer Jan 2024.

back to top
Last updated: 07/18/2024
The Trustees of the University of Pennsylvania